Substance use disorder stories

Oct 13, 2026

New trial to examine GLP-1 drugs' impact on criminal justice interactions, employment and housing

A newly announced clinical trial will test whether GLP-1 weight loss drugs can improve outcomes related to criminal justice system interactions, employment, and housing stability, expanding beyond existing trials examining the medications' effects on substance use disorders and other health conditions.

Oct 13, 20264 sources

Top claims

▪Research presented at the European Respiratory Society Congress linked GLP-1 medications to reduced asthma attacks and chronic obstructive pulmonary disease flare-ups.
▪A clinical trial published in the New England Journal of Medicine showed 62.9% of metabolic dysfunction-associated steatohepatitis patients taking semaglutide achieved disease resolution without worsening liver fibrosis, compared with 34.3% taking placebo.
▪A study in Lancet Psychiatry using U.S. health records showed people with schizophrenia taking GLP-1 drugs for diabetes were 24% less likely to be admitted to psychiatric hospitals.

Subtopics

Clinical trials1 Criminal justice reform1 GLP-1 drugs1 Weight loss medications1

Related timelines